FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates treating bacterial infections. Disclosed is a antibacterial combination containing (a) at least one antibacterial agent selected from cefepime, cefpirome, or salts thereof; and (b) tazobactam or salt thereof; said combination is further characterised by that it contains: (i) 1 g of antibacterial agent and 1 g tazobactam; or (ii) 2 g antibacterial agent and 2 g tazobactam; or (iii) 0.5 g antibacterial agent and 0.5 g tazobactam (versions). Disclosed is use of disclosed versions of antibacterial combination for treating or controlling a bacterial infection in a patient (versions).
EFFECT: technical result consists in synergetic antibacterial action and efficiency against bacterial infection caused by highly resistant strains, forming a beta-lactamase in a wide range.
15 cl, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBACTERIAL COMPOSITIONS | 2017 |
|
RU2813568C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING BETA-LACTAM ANTIBIOTIC, SULBACTAM AND BETA-LACTAMASE INHIBITOR | 2011 |
|
RU2569059C2 |
| ANTIBACTERIAL COMPOSITIONS AND METHODS | 2017 |
|
RU2779346C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIBACTERIAL AGENTS | 2014 |
|
RU2702361C2 |
| INTENDED FOR INJECTION COMPOSITIONS FOR OVERCOMING BETA-LACTAMASE-MEDIATED RESISTANCE TO ANTIBIOTICS WITH APPLICATION OF BETA-LACTAMASE INHIBITOR | 2005 |
|
RU2397768C2 |
| ANTIBACTERIAL COMPOSITIONS | 2013 |
|
RU2646798C2 |
| TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS | 2013 |
|
RU2671485C2 |
| CEFTAROLINE-INCLUDING COMPOSITIONS AND METHODS OF TREATMENT | 2009 |
|
RU2524665C2 |
| PHARMACEUTICAL COMPOSITIONS, CONTAINING SULBACTAM AND BETA-LACTAMASE INHIBITOR | 2011 |
|
RU2560846C1 |
| 1,6-DIAZABICYCLO[3,2,1]OCTAN-7-ONE DERIVATIVES AND USING THEM FOR TREATING BACTERIAL INFECTIONS | 2012 |
|
RU2578370C2 |
